e ISSN- 2249-7668

Print ISSN- 2249-7676

ISSN

2249-7676

e ISSN

2249-7668

Publisher

pharmacology and toxicology

RISK OF FAILURE AND TOXICITY OF ISONIAZID WITHOUT THERAPEUTIC DRUG MONITORING
Author / Afflication
Mamadou Kamagate

Clinical Pharmacology Department, UFR-SMB, University Alassane Ouattara, Bouaké, Côte d’Ivoire.
Alimata Sandia Bakayoko-Yeo-Ténena

Pneumo-phithisiology Department, UFRSMA, CHU Treichville, Cote d’Ivoire
Kanga Sita N’zué

Clinical Pharmacology Department, UFR-SMB, University Alassane Ouattara, Bouaké, Côte d’Ivoire.
Boko Alexandre Kouassi

Pneumo-phithisiology Department, UFRSMA, CHU Cocody, Cote d’Ivoire
Augustine Kakou

Clinical Pharmacology Department, UFR-SMA, University Félix Houphouet-Boigny, Abidjan, Cote d’Ivoire.
Thérèse Daubrey-Potey

Clinical Pharmacology Department, UFR-SMA, University Félix Houphouet-Boigny, Abidjan, Cote d’Ivoire.
Zakaria Koné

Pneumo-phithisiology Department, UFRSMA, CHU Treichville, Cote d’Ivoire
Yaya Dao

Pneumo-phithisiology Department, UFRSMA, CHU Treichville, Cote d’Ivoire
Elisabeth Aka-Danguy

Pneumo-phithisiology Department, UFRSMA, CHU Cocody, Cote d’Ivoire
Kouao M Serge Domoua

Pneumo-phithisiology Department, UFRSMA, CHU Treichville, Cote d’Ivoire
Henri Die-Kakou

Clinical Pharmacology Department, UFR-SMA, University Félix Houphouet-Boigny, Abidjan, Cote d’Ivoire.
Keywords
Acetylator Phenotype ,Isoniazid ,Failure ,Toxicity ,Therapeutic Drug Monitoring ,
Abstract

Isoniazid (INH), a major antitubercular agent is subjected to an acetylating polymorphism. So Slow Acetylators risk an exaggerated accumulation of INH and Fast Acetylators are likely to see the drug become ineffective more quickly. The objective was to determine the risk of inefficiency and toxicity of INH from its acetylator phenotype. We carried out a prospective multicentric study in two pneumo-phthisiology Departments for 12 months. This study concerned patients presenting a first episode of pulmonary tuberculosis who have given their informed consent. Acetylator phenotype was determined by using Vivien method. We recruited 48 patients. The sex ratio and the mean age were similar in the groups. The serum level of isoniazid obtained at the third hour allowed to noting that only 25% of the patients were in the therapeutic zone and 75% were outside of therapeutic zone (15% in failure zone and 60% in the toxic zone). Among the Fast Acetylators, 19.3% (6/31) were in infratherapeutic zone and 41.9% (13/31) in toxic zone, while 94.1% of the Slow acetylators (16/17) were in toxic zone. The majority of patients in infratherapeutic zone (85.7%) was Very Fast Acetylators and received 5 mg/kg/d of INH. The comparison of the average doses according to the weight and recommended doses after measurement of the INH were respectively 5.58 against 7.09 mg/kg/d for Fast Acetylators and 5.29 against 2.12 mg/kg/d for Slow Acetylators. The unexpected event risk of AR/AL was of 2.02 (IC95% : 0.81-5.22). The determination of the acetylator phenotype of patients with tuberculosis permitted to specify the isoniazid dosage. The higher serum level makes run the risk of intolerance and the lower serum levels risk may be ineffective and allow consequently to the selection of resistant bacilli.

Volume / Issue / Year

8 , 1 , 2018

Starting Page No / Endling Page No

1 - 10